TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1623898

Group type: EXPERIMENTAL
Intervention: Placebo/Codeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Quinidine/Codeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Quinidine/Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo/Placebo
Number of subjects: 16
Study: 6099262

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29524473

Group type: EXPERIMENTAL
Intervention: Healthy School Start intervention
Number of subjects: 29
Study: 28463044

Group type: EXPERIMENTAL
Intervention: Vibrating-mesh nebulizer (VN)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 6
Study: 25695403

Group type: EXPERIMENTAL
Intervention: MK-7123 50 mg
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: MK-7123
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 24179013

Group type: EXPERIMENTAL
Intervention: Antioxidative therapy (N-acetyl cysteine or MP865)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients (CKD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Controls (Healthy Subjects)
Number of subjects: 15
Study: 21931024

Group type: EXPERIMENTAL
Intervention: Early discharge to receive identical antibiotic treatment at home
Number of subjects: 117

Group type: COMPARATOR
Intervention: Continued inpatient antibiotic therapy
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both arms (home and hospital)
Number of subjects: 117
Study: 19057627

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with local anesthetic (lidocaine 0.5%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 42
Study: 16879461

Group type: COMPARATOR
Intervention: Bupivacaine 7.5 mg alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Bupivacaine 7.5 mg with 10 microg of fentanyl
Number of subjects: 108
Study: 14753029

Group type: EXPERIMENTAL
Intervention: 100 mg nimesulid bd.
Number of subjects: 200

Group type: COMPARATOR
Intervention: 275 mg naproxen bd.
Number of subjects: 200
Study: 10067689

Group type: EXPERIMENTAL
Intervention: EZ-M vaccine
Number of subjects: 0
Study: 7669532

Group type: EXPERIMENTAL
Intervention: Community-based, multidisciplinary and integrated education programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline data from participating communities
Number of subjects: 0
Study: 1975045

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2175

Group type: EXPERIMENTAL
Intervention: Good adherence (taking > 75% of prescribed medication)
Number of subjects: 2175
Study: 7029004

Group type: EXPERIMENTAL
Intervention: Glucose/electrolyte solution
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sugar/salt solution
Number of subjects: 61
Study: 31924365

Group type: EXPERIMENTAL
Intervention: Preoperative noninvasive ventilation (NIV) for at least 7 days and 4 hours/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: No NIV (control group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Preoperative noninvasive ventilation (NIV)
Number of subjects: 300
Study: 30961658

Group type: EXPERIMENTAL
Intervention: Sodium benzoate as an adjunctive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28535237

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1-time or 2-time injection of 500 mg or 1000 mg according to body weight)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 454
Study: 26592217

Group type: EXPERIMENTAL
Intervention: Pilates Method
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 56
Study: 22552593

Group type: EXPERIMENTAL
Intervention: Embrace (moisture-tolerant sealant)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Helioseal (conventional sealant)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 55

Group type: COMPARATOR
Intervention: Helioseal
Number of subjects: 55
Study: 21430302

Group type: EXPERIMENTAL
Intervention: Lay health advisor (LHA) intervention consisting of two in-person visits, two phone calls, and four postcards.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Lay health advisor (LHA) intervention (self-report data).
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (control group, self-report data).
Number of subjects: 286
Study: 19203986

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 50
Study: 17546385

Group type: EXPERIMENTAL
Intervention: Experimental group (20 cases)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (18 cases)
Number of subjects: 38
Study: 15214901

Group type: EXPERIMENTAL
Intervention: Eight shower or bath oils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (as a control)
Number of subjects: 0
Study: 11802949

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (study group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Invasive ventilation (control group)
Number of subjects: 24
Study: 9588731

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 50 mg/kg/day (maximum 2,000 mg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9306028

Group type: EXPERIMENTAL
Intervention: Eve 20 (20 micrograms ethinyl estradiol, 500 micrograms norethisterone)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lovelle (20 micrograms ethinyl estradiol, 150 micrograms desogestrel)
Number of subjects: 118
Study: 2052798

Group type: EXPERIMENTAL
Intervention: hCG vaccine
Number of subjects: 0
Study: 7020775

Group type: EXPERIMENTAL
Intervention: Biofeedback group (EMG feedback from hip extensors)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (self-relaxation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Relaxation group (modified progressive relaxation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Biofeedback plus relaxation group (relaxation and EMG hip extensor feedback)
Number of subjects: 25
Study: 31530444

Group type: EXPERIMENTAL
Intervention: Zona pellucida-free blastocysts
Number of subjects: 419

Group type: COMPARATOR
Intervention: Zona intact blastocysts (Control)
Number of subjects: 419
Study: 28926295

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg plaster
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 132
Study: 26079649

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - 12 months duration, heavy resistance exercises (5×10RM leg presses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 13
Study: 24134491

Group type: EXPERIMENTAL
Intervention: Lifestyle Functional Exercise (LiFE) program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Current exercise program (control)
Number of subjects: 150
Study: 20621449

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n = 169)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (n = 166)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Between-group differences
Number of subjects: 335
Study: 18560816

Group type: EXPERIMENTAL
Intervention: Perfusion-weighted magnetic resonance imaging (PW-MRI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: SAH patients with severe CVS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 51

Group type: COMPARATOR
Intervention: SAH patients without CVS
Number of subjects: 51
Study: 16555056

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (L)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Insulin treatment (I)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined treatment (L+I)
Number of subjects: 28
Study: 12951881

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in preeclampsia group
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in edema group
Number of subjects: 440

Group type: COMPARATOR
Intervention: Bioelectrical impedance analysis (BIA) in control group
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: BIA as a predictor
Number of subjects: 440
Study: 11284211

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 52

Group type: COMPARATOR
Intervention: DTSQ(S)
Number of subjects: 52
Study: 8728123

Group type: EXPERIMENTAL
Intervention: 10 weeks of moderate dose (30 mg/d) beta‐carotene
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1678453

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: ondansetron
Number of subjects: 112

Group type: COMPARATOR
Intervention: dexamethasone
Number of subjects: 112
Study: 6136286

Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol 2 mg kg‐1 i.v. bolus injection
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol infusion (150 micrograms kg‐1 min‐1 for 30 min and 75 micrograms kg‐1 min‐1 thereafter)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diisopropyl phenol infusion
Number of subjects: 52
Study: 31969177

Group type: EXPERIMENTAL
Intervention: Crenezumab (300 mg subcutaneously every 2 weeks or 15 mg/kg, 30 mg/kg, 45 mg/kg, 60 mg/kg, or 120 mg/kg intravenously every 4 weeks)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Crenezumab
Number of subjects: 131
Study: 31186524

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study: 28818049

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 217

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 217

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 217
Study: 27802555

Group type: EXPERIMENTAL
Intervention: Usual care plus OMT (OMT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care plus placebo ultrasound treatment (PUT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care only (UCO)
Number of subjects: 400
Study: 24999798

Group type: EXPERIMENTAL
Intervention: 24-h average aortic SBP
Number of subjects: 229

Group type: COMPARATOR
Intervention: 24-h average brachial SBP
Number of subjects: 229
Study: 23097606

Group type: EXPERIMENTAL
Intervention: APP ON phases
Number of subjects: 50

Group type: COMPARATOR
Intervention: APP OFF phases
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: APP OFF and APP ON phases
Number of subjects: 50
Study: 19596934

Group type: EXPERIMENTAL
Intervention: Amitriptyline (target dose, 100 mg daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 17224708

Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline BMI category (normal-weight)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline BMI category (overweight)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline BMI category (obese)
Number of subjects: 50
Study: 14694498

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation (5 g daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11813077

Group type: EXPERIMENTAL
Intervention: Physical activities (walking)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Self-reported health status
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Chronic diseases
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 89
Study: 9825105

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg orally once a day or 200 mg intravenously twice a day for 2‐4 days followed by oral use for 6‐8 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 60
Study: 7621388

Group type: EXPERIMENTAL
Intervention: Clomipramine alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Behaviour therapy alone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clomipramine and behaviour therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 2691256

Group type: EXPERIMENTAL
Intervention: 250 micrograms folic acid (FA)/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 4577839

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gefarnate
Number of subjects: 68
Study: 31934790

Group type: EXPERIMENTAL
Intervention: Interactive narrative
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional linear narrative
Number of subjects: 0
Study: 31238631

Group type: EXPERIMENTAL
Intervention: Watch and wait (W&W) strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watch and wait (W&W) strategy after cCR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 0
Study: 28348185

Group type: EXPERIMENTAL
Intervention: Surgical fixation followed by mobilisation in a walking boot for 6 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-surgical management in a walking boot for 6 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-surgical group
Number of subjects: 160
Study: 25444803

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (3.75 μg antigen with half a standard dose of MF59)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (7.5 μg antigen with a full dose of MF59)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (15 μg formulation)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (3.75 μg antigen)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: All A/H1N1 vaccine formulations
Number of subjects: 354
Study: 22405535

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 24
Study: 22063370

Group type: EXPERIMENTAL
Intervention: Methadone (20mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Morphine (20mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 19691149

Group type: EXPERIMENTAL
Intervention: Home‐based care management for 2 years by a nurse practitioner and social worker
Number of subjects: 951

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 951
Study: 17005278

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for AVMs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for brain metastases
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for both AVMs and brain metastases
Number of subjects: 40
Study: 12760628

Group type: EXPERIMENTAL
Intervention: Stronger task with progressively delayed onset of stimulus attribute
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separation of response sets of the tasks
Number of subjects: 0
Study: 11296514

Group type: EXPERIMENTAL
Intervention: Micro-etched molar bands
Number of subjects: 79

Group type: COMPARATOR
Intervention: Untreated molar bands
Number of subjects: 79
Study: 9063787

Group type: EXPERIMENTAL
Intervention: Dermagraft‐TC Red (cryopreserved to maintain fibroblast viability)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dermagraft‐TC Blue (frozen without efforts to maintain fibroblast viability)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cryopreserved human cadaver allograft skin (HCAS)
Number of subjects: 10
Study: 8287640

Group type: EXPERIMENTAL
Intervention: Mild hypoglycaemia (3.3 mmol/l)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mild hypoglycaemia (3.7 mmol/l)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderate hypoglycaemia (2.5 mmol/l) after mild hypoglycaemia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (blood glucose maintained at 4.5 mmol/l)
Number of subjects: 11
Study: 3458726

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 0.5% zinc citrate (ZCT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 0.4% stannous fluoride
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice
Number of subjects: 88
Study: 30053162

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo (initially) then re-randomized to ixekizumab
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Overall safety profile of ixekizumab
Number of subjects: 310
Study: 27609106

Group type: EXPERIMENTAL
Intervention: Carboxyethyl lysine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Methylglyoxal hydroimidazolone
Number of subjects: 168
Study: 25110439

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) administered at a dose of 3 ng/kg per min for 10 min intravenously before ESWL
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No Cholecystokinin (no CCK)
Number of subjects: 148
Study: 22273629

Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 176
Study: 20528836

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 18809608

Group type: EXPERIMENTAL
Intervention: Vaccination with the six-peptide melanoma vaccine
Number of subjects: 39
Study: 16138265

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Glimepiride (1-6 mg)
Number of subjects: 173
Study: 12374234

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nitrates (0.1 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nitrates plus Propranolol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Propranolol vs. Placebo (NaCl)
Number of subjects: 31
Study: 10196647

Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre (canalith repositioning manoeuvre)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 41
Study: 7558945

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin 100 mg/m2 Day 1, 5-fluorouracil 1000 mg/m2 24-h infusion Days 2, 3, and 4 before radical radiotherapy, and four cycles of postradiotherapy chemotherapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 82
Study: 2130365

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 21
Study: 855810

Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 260 mg of tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 390 mg of tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 520 mg of tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 260 mg of tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 390 mg of tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 520 mg of tryptophan
Number of subjects: 0
Study: 30222478

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study: 27902493

Group type: EXPERIMENTAL
Intervention: Intravenous amisulpride (5 mg)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 689
Study: 25467617

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin plus insulin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin treated groups
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin group
Number of subjects: 150
Study: 23563442

Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Daily wear (DW)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW) after 1 month
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW) after the first night
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: NGAL profile
Number of subjects: 47
Study: 20837368

Group type: EXPERIMENTAL
Intervention: P wave wavelet analysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy individuals without history of PAF)
Number of subjects: 50
Study: 18091330

Group type: EXPERIMENTAL
Intervention: Cholesteatoma group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normally hearing nonsyndromic controls
Number of subjects: 31
Study: 17315796

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Vitremer)
Number of subjects: 27
Study: 15189587

Group type: EXPERIMENTAL
Intervention: Accusations made by individuals with faults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accusations made by individuals with no faults
Number of subjects: 0
Study: 11128173

Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 181